FDA — authorised 10 November 2019
- Marketing authorisation holder: ELI LILLY AND CO
- Status: approved
🇺🇸 Reyvow in United States
FDA authorised Reyvow on 10 November 2019
Marketing authorisations
FDA
- Application: ANDA219350
- Marketing authorisation holder: QILU PHARMACEUTICAL CO., LTD.
- Local brand name: LASMIDITAN
- Indication: TABLET
- Status: approved
FDA
- Application: ANDA219669
- Marketing authorisation holder: HUMANWELL PHARMACEUTICAL US INC
- Local brand name: LASMIDITAN
- Indication: TABLET
- Status: approved
Reyvow in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United States
Frequently asked questions
Is Reyvow approved in United States?
Yes. FDA authorised it on 10 November 2019; FDA has authorised it; FDA has authorised it.
Who is the marketing authorisation holder for Reyvow in United States?
ELI LILLY AND CO holds the US marketing authorisation.